A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity.

Standard

A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity. / Huber, Magdalena; Heink, Sylvia; Grothe, Henrike; Guralnik, Anna; Reinhard, Katharina; Elflein, Karin; Hünig, Thomas; Mittrücker, Hans Willi; Brüstle, Anne; Kamradt, Thomas; Lohoff, Michael.

In: EUR J IMMUNOL, Vol. 39, No. 7, 7, 2009, p. 1716-1725.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Huber, M, Heink, S, Grothe, H, Guralnik, A, Reinhard, K, Elflein, K, Hünig, T, Mittrücker, HW, Brüstle, A, Kamradt, T & Lohoff, M 2009, 'A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity.', EUR J IMMUNOL, vol. 39, no. 7, 7, pp. 1716-1725. <http://www.ncbi.nlm.nih.gov/pubmed/19544308?dopt=Citation>

APA

Huber, M., Heink, S., Grothe, H., Guralnik, A., Reinhard, K., Elflein, K., Hünig, T., Mittrücker, H. W., Brüstle, A., Kamradt, T., & Lohoff, M. (2009). A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity. EUR J IMMUNOL, 39(7), 1716-1725. [7]. http://www.ncbi.nlm.nih.gov/pubmed/19544308?dopt=Citation

Vancouver

Huber M, Heink S, Grothe H, Guralnik A, Reinhard K, Elflein K et al. A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity. EUR J IMMUNOL. 2009;39(7):1716-1725. 7.

Bibtex

@article{11bc9be8984f4b73b9d069c5608b168e,
title = "A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity.",
abstract = "Activation of naive CD8(+) T cells with antigen in the absence of skewing cytokines triggers their differentiation into effector CTL, which induces death of target cells. We show that CD8(+) T cells activated in the presence of the cytokines IL-6 or IL-21 plus TGF-beta similar to CD4(+) T cells, develop into IL-17-producing (Tc17) cells. These cells display greatly suppressed cytotoxic function along with low levels of the CTL markers: T-box transcription factor Eomesodermin, granzyme B and IFN-gamma. Instead, these cells express hallmark molecules of Th17 program including retinoic acid receptor-related orphan receptor (ROR)gammat, RORalpha, IL-21 and IL-23R. The expression of the type 17 master regulator RORgammat is causally linked to Tc17 generation, because its overexpression stimulates production of IL-17 in the presence of IL-6 or IL-21. Both, upregulation of the type 17 program as well as suppression of CTL differentiation are STAT3 dependent. Furthermore, Tc17 cells producing IL-17 but not granzyme B are also detectable in EAE, a mouse model for multiple sclerosis. Our data point to the existence of mutually exclusive CTL and Tc17 developmental pathways in vitro and in vivo.",
author = "Magdalena Huber and Sylvia Heink and Henrike Grothe and Anna Guralnik and Katharina Reinhard and Karin Elflein and Thomas H{\"u}nig and Mittr{\"u}cker, {Hans Willi} and Anne Br{\"u}stle and Thomas Kamradt and Michael Lohoff",
year = "2009",
language = "Deutsch",
volume = "39",
pages = "1716--1725",
journal = "EUR J IMMUNOL",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag GmbH",
number = "7",

}

RIS

TY - JOUR

T1 - A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity.

AU - Huber, Magdalena

AU - Heink, Sylvia

AU - Grothe, Henrike

AU - Guralnik, Anna

AU - Reinhard, Katharina

AU - Elflein, Karin

AU - Hünig, Thomas

AU - Mittrücker, Hans Willi

AU - Brüstle, Anne

AU - Kamradt, Thomas

AU - Lohoff, Michael

PY - 2009

Y1 - 2009

N2 - Activation of naive CD8(+) T cells with antigen in the absence of skewing cytokines triggers their differentiation into effector CTL, which induces death of target cells. We show that CD8(+) T cells activated in the presence of the cytokines IL-6 or IL-21 plus TGF-beta similar to CD4(+) T cells, develop into IL-17-producing (Tc17) cells. These cells display greatly suppressed cytotoxic function along with low levels of the CTL markers: T-box transcription factor Eomesodermin, granzyme B and IFN-gamma. Instead, these cells express hallmark molecules of Th17 program including retinoic acid receptor-related orphan receptor (ROR)gammat, RORalpha, IL-21 and IL-23R. The expression of the type 17 master regulator RORgammat is causally linked to Tc17 generation, because its overexpression stimulates production of IL-17 in the presence of IL-6 or IL-21. Both, upregulation of the type 17 program as well as suppression of CTL differentiation are STAT3 dependent. Furthermore, Tc17 cells producing IL-17 but not granzyme B are also detectable in EAE, a mouse model for multiple sclerosis. Our data point to the existence of mutually exclusive CTL and Tc17 developmental pathways in vitro and in vivo.

AB - Activation of naive CD8(+) T cells with antigen in the absence of skewing cytokines triggers their differentiation into effector CTL, which induces death of target cells. We show that CD8(+) T cells activated in the presence of the cytokines IL-6 or IL-21 plus TGF-beta similar to CD4(+) T cells, develop into IL-17-producing (Tc17) cells. These cells display greatly suppressed cytotoxic function along with low levels of the CTL markers: T-box transcription factor Eomesodermin, granzyme B and IFN-gamma. Instead, these cells express hallmark molecules of Th17 program including retinoic acid receptor-related orphan receptor (ROR)gammat, RORalpha, IL-21 and IL-23R. The expression of the type 17 master regulator RORgammat is causally linked to Tc17 generation, because its overexpression stimulates production of IL-17 in the presence of IL-6 or IL-21. Both, upregulation of the type 17 program as well as suppression of CTL differentiation are STAT3 dependent. Furthermore, Tc17 cells producing IL-17 but not granzyme B are also detectable in EAE, a mouse model for multiple sclerosis. Our data point to the existence of mutually exclusive CTL and Tc17 developmental pathways in vitro and in vivo.

M3 - SCORING: Zeitschriftenaufsatz

VL - 39

SP - 1716

EP - 1725

JO - EUR J IMMUNOL

JF - EUR J IMMUNOL

SN - 0014-2980

IS - 7

M1 - 7

ER -